Biomarkers in adult congenital heart disease heart failure

Heart Failure Clinics

Volumn 10, Issue 1, 2014, Pages 43-56

  Ohuchi, Hideo ^a   Diller, Gerhard Paul ^b  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Adult congenital heart disease; Biomarker; Heart failure; Mortality; Natriuretic peptide; Ventricular dysfunction

Indexed keywords

ADIPONECTIN; ALDOSTERONE; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CATECHOLAMINE; COLLAGEN TYPE 3; CREATINE KINASE MB; ENDOTHELIN 1; INTERLEUKIN 6; MATRIX METALLOPROTEINASE; MYELOPEROXIDASE; N(G),N(G) DIMETHYLARGININE; NORADRENALIN; OXIDIZED LOW DENSITY LIPOPROTEIN; RENIN; TROPONIN I; TROPONIN T; TUMOR NECROSIS FACTOR ALPHA;

ARTERIAL OXYGEN SATURATION; CARDIOPULMONARY EXERCISE TEST; CARDIOVASCULAR MAGNETIC RESONANCE; CELL DAMAGE; CELL STRESS; COMPUTER ASSISTED TOMOGRAPHY; CONGENITAL HEART DISEASE; DIAGNOSTIC VALUE; DISEASE SEVERITY; ECHOCARDIOGRAPHY; EXTRACELLULAR MATRIX; HEART MUSCLE ISCHEMIA; HEART SIZE; HORMONE DETERMINATION; HUMAN; HYPERTENSION; INFLAMMATION; LUNG FUNCTION; MUSCLE CELL; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PREGNANCY; PROGNOSIS; PULMONARY HYPERTENSION; PULMONARY VALVE INSUFFICIENCY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; TURNAROUND TIME; VALVULAR HEART DISEASE;

ADULT CONGENITAL HEART DISEASE; BIOMARKER; HEART FAILURE; MORTALITY; NATRIURETIC PEPTIDE; VENTRICULAR DYSFUNCTION;

ADULT; BIOLOGICAL MARKERS; FEMALE; HEART DEFECTS, CONGENITAL; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDES; NOREPINEPHRINE; PREDICTIVE VALUE OF TESTS; PREGNANCY; PROGNOSIS; STATISTICS AS TOPIC; VENTRICULAR DYSFUNCTION;

EID: 84888062862     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2013.09.020     Document Type: Review

References (49)

1. Braunwald E. Biomarkers in heart failure. NEngl J Med 2008, 358:2148-2159.
2. Morrow D.A., de Lemos J.A. Benchmarks for the assessment of novel cardiovascular biomarkers. Circulation 2007, 115:949-952.
3. Tulevski I.I., Groenink M., van Der Wall E.E., et al. Increased brain and atrial natriuretic peptides in patients with chronic right ventricular pressure overload: correlation between plasma neurohormones and right ventricular dysfunction. Heart 2001, 86:27-30.
4. Bolger A.P., Sharma R., Li W., et al. Neurohormonal activation and the chronic heart failure syndrome in adults with congenital heart disease. Circulation 2002, 106:92-99.
5. Book W.M., Hott B.J., McConnell M. B-type natriuretic peptide levels in adults with congenital heart disease and right ventricular failure. Am J Cardiol 2005, 95:545-546.
6. Law Y.M., Keller B.B., Feingold B.M., et al. Usefulness of plasma B-type natriuretic peptide to identify ventricular dysfunction in pediatric and adult patients with congenital heart disease. Am J Cardiol 2005, 95:474-478.
7. Perlowski A.A., Aboulhosn J., Castellon Y., et al. Relation of brain natriuretic peptide to myocardial performance index in adults with congenital heart disease. Am J Cardiol 2007, 100:110-114.
8. Trojnarska O., Gwizdala A., Katarzynski S., et al. TheBNP concentrations and exercise capacity assessment with cardiopulmonary stress test in cyanotic adult patients with congenital heart diseases. Int J Cardiol 2010, 139:241-247.
9. Giannakoulas G., Dimopoulos K., Bolger A.P., et al. Usefulness of natriuretic peptide levels to predict mortality in adults with congenital heart disease. Am J Cardiol 2010, 105:869-873.
10. Tutarel O., Denecke A., Bode-Böger S.M., et al. Asymmetrical dimethylarginine-more sensitivethan NT-proBNP to diagnose heart failure in adults with congenital heart disease. PLoS One 2012, 7:e33795.
11. Ohuchi H., Takasugi H., Ohashi H., et al. Stratification of pediatric heart failure on the basis of neurohormonal and cardiac autonomic nervous activities in patients with congenital heart disease. Circulation 2003, 108:2368-2376.
12. Nagaya N., Nishikimi T., Okano Y., et al. Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension. JAm Coll Cardiol 1998, 31:202-208.
13. Nagaya N., Nishikimi T., Uematsu M., et al. Secretion patterns of brain natriuretic peptide and atrial natriuretic peptide in patients with or without pulmonary hypertension complicating atrial septal defect. Am Heart J 1998, 136:297-301.
14. Nagaya N., Nishikimi T., Uematsu M., et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 2000, 102:865-870.
15. Brili S., Alexopoulos N., Latsios G., et al. Tissue Doppler imaging and brain natriuretic peptide levels in adults with repaired tetralogy of Fallot. JAm Soc Echocardiogr 2005, 18:1149-1154.
16. Norozi K., Buchhorn R., Kaiser C., et al. Plasma N-terminal pro-brain natriuretic peptide as a marker of right ventricular dysfunction in patients with tetralogy of Fallot after surgical repair. Chest 2005, 128:2563-2570.
17. Norozi K., Buchhorn R., Bartmus D., et al. Elevated brain natriuretic peptide and reduced exercise capacity in adult patients operated on for tetralogy of Fallot is due to biventricular dysfunction as determined by the myocardial performance index. Am J Cardiol 2006, 97:1377-1382.
18. Schoen S.P., Zimmermann T., Kittner T., et al. NT-proBNP correlates with right heart haemodynamic parameters and volumes in patients with atrial septal defects. Eur J Heart Fail 2007, 9:660-666.
19. Festa P., Ait-Ali L., Prontera C., et al. Amino-terminal fragment of pro-brain natriuretic hormone identifies functional impairment and right ventricular overload in operated tetralogy of Fallot patients. Pediatr Cardiol 2007, 28:339-345.
20. Koch A.M., Zink S., Glöckler M., et al. Plasma levels of B-type natriuretic peptide in patients with tetralogy of Fallot after surgical repair. Int J Cardiol 2010, 143:130-134.
21. Oosterhof T., Tulevski I.I., Vliegen H.W., et al. Effects ofvolume and/or pressure overload secondary to congenital heart disease (tetralogy of Fallot or pulmonary stenosis) on right ventricular function using cardiovascular magnetic resonance and B-type natriuretic peptide levels. Am J Cardiol 2006, 97:1051-1055.
22. Westhoff-Bleck M., Girke S., Breymann T., et al. Pulmonary valve replacement in chronic pulmonary regurgitation in adults with congenital heart disease: impact of preoperative QRS-duration and NT-proBNP levels on postoperative right ventricular function. Int J Cardiol 2011, 151:303-306.
23. Norozi K., Buchhorn R., Alpers V., et al. Relation of systemic ventricular function quantified by myocardial performance index (Tei) to cardiopulmonary exercise capacity in adults after Mustard procedure for transposition of the great arteries. Am J Cardiol 2005, 96:1721-1725.
24. Dore A., Houde C., Chan K.L., et al. Angiotensin receptor blockade and exercise capacity in adults with systemic right ventricles: a multicenter, randomized, placebo-controlled clinical trial. Circulation 2005, 112:2411-2416.
25. Chow P.C., Cheung E.W., Chong C.Y., et al. Brain natriuretic peptide as a biomarker of systemic right ventricular function in patients with transposition ofgreat arteries after atrial switch operation. Int J Cardiol 2008, 127:192-197.
26. Vogt M., Kühn A., Wiese J., et al. Reduced contractile reserve of the systemic right ventricle under dobutamine stress is associated with increased brain natriuretic peptide levels in patients with complete transposition after atrial repair. Eur J Echocardiogr 2009, 10:691-694.
27. Schaefer A., Tallone E.M., Westhoff-Bleck M., et al. Relation of diastolic and systolic function, exercise capacity and brain natriuretic peptide in adults after Mustard procedure for transposition of the great arteries. Cardiology 2010, 117:112-117.
28. Plymen C.M., Hughes M.L., Picaut N., et al. The relationship of systemic right ventricular function to ECG parameters and NT-proBNP levels in adults with transposition of the great arteries late after Senning or Mustard surgery. Heart 2010, 96:1569-1573.
29. Szymański P., Klisiewicz A., Lubiszewska B., et al. Gender differences in angiotensin II and aldosterone secretion in patients with pressure overloaded systemic right ventricles are similar to those observed in systemic arterial hypertension. Int J Cardiol 2011, 147:366-370.
30. Winter M.M., Bouma B.J., van Dijk A.P., et al. Relation of physical activity, cardiac function, exercise capacity, and quality of life in patients with a systemic right ventricle. Am J Cardiol 2008, 102:1258-1262.
31. Koch A.M., Zink S., Singer H. B-type natriuretic peptide in patients with systemic right ventricle. Cardiology 2008, 110:1-7.
32. Garg R., Raman S.V., Hoffman T.M., et al. Serum markers of systemic right ventricular function and exercise performance. Pediatr Cardiol 2008, 29:641-648.
33. Larsson D.A., Meurling C.J., Holmqvist F., et al. The diagnostic and prognostic value of brain natriuretic peptides in adults with a systemic morphologically right ventricle or Fontan-type circulation. Int J Cardiol 2007, 114:345-351.
34. Trojnarska O., Gwizdała A., Katarzyński S., et al. Evaluation of exercise capacity with cardiopulmonary exercise testing and BNP levels in adult patients with single or systemic right ventricles. Arch Med Sci 2010, 6:192-197.
35. Inai K., Nakanishi T., Nakazawa M. Clinical correlation and prognostic predictive value of neurohumoral factors in patients late after the Fontan operation. Am Heart J 2005, 150:588-594.
36. Motoki N., Ohuchi H., Miyazaki A., et al. Clinical profiles of adult patients with single ventricular physiology. Circ J 2009, 73:1711-1716.
37. Hopkins W.E., Hall C. Paradoxical relationship between N-terminal proatrial natriuretic peptide and filling pressure in adults with cyanotic congenital heart disease. Circulation 1997, 96:2215-2220.
38. Hopkins W.E., Chen Z., Fukagawa N.K., et al. Increased atrial and brain natriuretic peptides in adults with cyanotic congenital heart disease: enhanced understanding of the relationship between hypoxia and natriuretic peptide secretion. Circulation 2004, 109:2872-2877.
39. Reardon L.C., Williams R.J., Houser L.S., et al. Usefulness of serum brain natriuretic peptide to predict adverse events in patients with the Eisenmenger syndrome. Am J Cardiol 2012, 110:1523-1526.
40. Diller G.P., Alonso-Gonzalez R., Kempny A., et al. B-type natriuretic peptide concentrations in contemporary Eisenmenger syndrome patients: predictive value and response to disease targeting therapy. Heart 2012, 98:736-742.
41. Schuuring MJ, van Riel AC, Vis JC, et al. High-sensitivity troponin T is associated with poor outcome in adults with pulmonary arterial hypertension due to congenital heart disease. Congenit Heart Dis, in press.
42. Saab F.G., Aboulhosn J.A. Hemodynamic characteristics of cyanotic adults with single-ventricle physiology without Fontan completion. Congenit Heart Dis 2013, 8:124-130.
43. Redfield M.M., Rodeheffer R.J., Jacobsen S.J., et al. Plasma brain natriuretic peptide concentration: impact of age and gender. JAm Coll Cardiol 2002, 40:976-982.
44. Tsutamoto T., Wada A., Sakai H., et al. Relationship between renal function and plasma brain natriuretic peptide in patients with heart failure. JAm Coll Cardiol 2006, 47:582-586.
45. Wold Knudsen C., Vik-Mo H., Omland T. Blood haemoglobin is an independent predictor of B-type natriuretic peptide (BNP). Clin Sci (Lond) 2005, 109:69-74.
46. Wang T.J., Larson M.G., Levy D., et al. Impact of obesity on plasma natriuretic peptide levels. Circulation 2004, 109:594-600.
47. Ohuchi H., Takasugi H., Ohashi H., et al. Abnormalities of neurohormonal and cardiac autonomic nervous activities relate poorly to functional status in Fontan patients. Circulation 2004, 110:2601-2608.
48. Tanous D., Siu S.C., Mason J., et al. B-type natriuretic peptide in pregnant women with heart disease. JAm Coll Cardiol 2010, 56:1247-1253.
49. Kamiya T., Iwamiya T., Neki R., et al. Outcome of pregnancy and effects on the right heart in women with repaired tetralogy of Fallot. Circ J 2012, 76:957-963.